AMICUS THERAPEUTICS, INC. Income Statement
FOLD / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 15 fiscal years. All figures from audited SEC 10-K filings.
AMICUS THERAPEUTICS, INC. reported $634M in revenue and $27M in net loss for FY2025. Revenue has grown at a 27.4% compound annual rate over the past 14 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -1.19 (distress zone, below 1.8 threshold)
- Negative profit margin: -10.6%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $634.2M | $528.3M | $399.4M | $329.2M | $305.5M | $260.9M | $182.2M | - | $36.9M | $5.0M | - | $1.2M | $363.0K | $18.4M | $21.4M |
| Cost of Revenue | $72.9M | $52.9M | $37.3M | $38.6M | $34.5M | $31.0M | $22.0M | $14.4M | $6.2M | $833.0K | - | - | - | - | - |
| Gross Profit | $561.3M | $475.4M | $362.0M | $290.6M | $271.0M | $229.8M | $160.3M | $76.8M | $30.7M | $4.1M | - | $1.2M | - | - | - |
| SG&A Expense | $383.5M | $323.4M | $275.3M | $213.0M | $192.7M | $156.4M | $169.9M | $127.2M | $88.7M | $71.2M | $47.3M | $20.7M | $18.9M | $19.4M | $19.9M |
| R&D Expense | $135.8M | $109.4M | $152.4M | $276.7M | $272.0M | $308.4M | $286.4M | $270.9M | $149.3M | $104.8M | $76.9M | $47.6M | $41.9M | $50.3M | $50.9M |
| Operating Income | $32.8M | $24.9M | -$77.2M | -$212.1M | -$206.4M | -$247.0M | -$304.0M | -$328.8M | -$442.0M | -$181.9M | -$130.4M | -$68.7M | -$64.2M | -$52.9M | -$50.9M |
| Interest Expense | - | - | $50.1M | $37.1M | $32.5M | $22.4M | $18.9M | $22.4M | $17.2M | $5.4M | $1.6M | $1.5M | $46.0K | $89.0K | $148.0K |
| Income Tax | $27.3M | $27.4M | $1.5M | -$5.5M | $8.9M | $2.6M | $478.0K | -$94.0K | -$165.1M | -$3.7M | - | -$1.1M | -$3.5M | -$3.2M | -$3.6M |
| Net Income | -$27.1M | -$56.1M | -$151.6M | -$236.6M | -$250.5M | -$276.9M | -$356.4M | -$349.0M | -$284.0M | -$200.0M | -$132.1M | -$68.9M | -$59.6M | -$48.8M | -$44.4M |
| EPS (Basic) | -$0.51 | -$0.82 | -$0.92 | -$1.07 | -$1.48 | -$1.07 | -$1.48 | - | - | - | - | - | - | - | - |
| EPS (Diluted) | -$0.51 | -$0.82 | -$0.92 | -$1.07 | -$1.48 | -$1.07 | -$1.48 | - | -$1.20 | -$0.93 | -$1.16 | -$1.07 | -$1.28 | -$1.98 | -$0.29 |
| Shares Outstanding | 299.0M | 293.6M | 281.1M | 278.9M | 262.1M | 258.9M | 240.4M | 185.8M | 142.7M | 125.0M | 95.6M | 62.0M | 34.7M | 34.7M | 34.5M |
| Gross Margin | 88.5% | 90.0% | 90.6% | 88.3% | 88.7% | 88.1% | 87.9% | - | 83.1% | 83.2% | - | 100.0% | - | - | - |
| Operating Margin | 5.2% | 4.7% | -19.3% | -64.4% | -67.6% | -94.7% | - | - | -1196.8% | -3668.6% | - | -5612.8% | -17680.7% | -287.5% | -237.4% |
| Profit Margin | -4.3% | -10.6% | -38.0% | -71.9% | -82.0% | -106.1% | -195.6% | - | -769.0% | -4034.7% | - | -5631.2% | -16427.8% | -265.0% | -207.2% |